BMY Stock Recent News

BMY LATEST HEADLINES

BMY Stock News Image - Zacks Investment Research

Investors are likely to focus on Opdivo's demand, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) posts Q1 results.

Zacks Investment Research 2024 Apr 22
BMY Stock News Image - Seeking Alpha

BMY has been upgraded to a Buy, with the stock already yielding 5.02% at the time of writing and the Seeking Alpha Quant still grading its dividend safety at B-. Combined with the promising profitability metrics and its overly discounted valuations, it now offers an attractive risk-reward ratio for value and dividend-oriented investors with long-term trajectory. We expect BMY to deliver a mixed FQ1'24 earnings call, attributed to the one-time IPR&D and milestones expenses from the recently closed Karuna, Rayzebio, and Mirati acquisitions.

Seeking Alpha 2024 Apr 22
BMY Stock News Image - Reuters

Bristol Myers Squibb and Cellares said on Monday they have reached a $380 million deal to supply CAR-T cell therapies to more patients.

Reuters 2024 Apr 22
BMY Stock News Image - The Motley Fool

Bristol Myers has an uncertain future, but with a strong track record and impressive cash flow it's still a top healthcare stock to own. Verizon Communications offers investors a mouth-watering yield without much risk.

The Motley Fool 2024 Apr 20
BMY Stock News Image - The Motley Fool

Healthcare stocks can be excellent choices for investors, offering a balance of safety and growth. Intuitive Surgical, Bristol Myers Squibb, and Novo Nordisk all have strong growth potential.

The Motley Fool 2024 Apr 19
BMY Stock News Image - InvestorPlace

The U.S. stock market continues to climb the wall of worry, despite persistent inflation and heightened geopolitical risks. The S&P 500 has returned 26% in the past 12 months, while the Wilshire 5000 index (a broader gauge of the total U.S. stock market) has gained 23% in the past year, not including dividends.

InvestorPlace 2024 Apr 17
BMY Stock News Image - The Motley Fool

Bristol Myers Squibb is turning on its innovative machine to get through recent patent cliffs. Novartis recently became a thinner company that is laser-focused on developing new medicines.

The Motley Fool 2024 Apr 17
BMY Stock News Image - Zacks Investment Research

Bristol Myers Squibb (BMY) closed the most recent trading day at $48.51, moving +0.48% from the previous trading session.

Zacks Investment Research 2024 Apr 15
BMY Stock News Image - Seeking Alpha

Bristol Myers Squibb's share price continues to move sideways despite several regulatory approvals for its innovative drugs in the past six months. On April 2, 2024, the EMA approved Reblozyl as a first-line treatment for anemia in certain patients with MDS. On March 14 of this year, Breyanzi was approved by the FDA to combat relapsed/refractory CLL and small lymphocytic lymphoma, which will help accelerate its sales growth.

Seeking Alpha 2024 Apr 12
BMY Stock News Image - Proactive Investors

Expectations for US biopharma companies' first quarter earnings are low given the typical seasonality across the sector and new healthcare plan signups, analysts at the Bank of America believe. “We don't expect many guidance changes; a stable earnings season should warrant continued generalist interest in biopharma,” the analysts wrote in a note.

Proactive Investors 2024 Apr 12
10 of 50